Literature DB >> 32294430

Cdk4 and Cdk6 Couple the Cell-Cycle Machinery to Cell Growth via mTORC1.

Jesús Romero-Pozuelo1, Gianluca Figlia1, Oguzhan Kaya2, Ana Martin-Villalba3, Aurelio A Teleman4.   

Abstract

Cell growth is coupled to cell-cycle progression in mitotically proliferating mammalian cells, but the underlying molecular mechanisms are not well understood. CyclinD-Cdk4/6 is known to phosphorylate RB to promote S-phase entry, but recent work suggests they have additional functions. We show here that CyclinD-Cdk4/6 activates mTORC1 by binding and phosphorylating TSC2 on Ser1217 and Ser1452. Pharmacological inhibition of Cdk4/6 leads to a rapid, TSC2-dependent reduction of mTORC1 activity in multiple human and mouse cell lines, including breast cancer cells. By simultaneously driving mTORC1 and E2F, CyclinD-Cdk4/6 couples cell growth to cell-cycle progression. Consistent with this, we see that mTORC1 activity is cell cycle dependent in proliferating neural stem cells of the adult rodent brain. We find that Cdk4/6 inhibition reduces cell proliferation partly via TSC2 and mTORC1. This is of clinical relevance, because Cdk4/6 inhibitors are used for breast cancer therapy.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cdk4; Cdk6; CycD; TSC2; abemaciclib; cell cycle; cell growth; mTORC1; palbociclib; ribociclib

Mesh:

Substances:

Year:  2020        PMID: 32294430     DOI: 10.1016/j.celrep.2020.03.068

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  26 in total

Review 1.  Applications and mechanisms of the cyclin-dependent kinase 4/6 inhibitor, PD-0332991, in solid tumors.

Authors:  Wenjian Chen; Wencheng Zhang; Miaomiao Chen; Chao Yang; Ting Fang; Haifeng Wang; Lola M Reid; Zhiying He
Journal:  Cell Oncol (Dordr)       Date:  2022-09-10       Impact factor: 7.051

2.  Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism.

Authors:  Maysa Abu-Khalaf; Chun Wang; Zhenchao Zhang; Rui Luo; Weelic Chong; Daniel P Silver; Frederick Fellin; Rebecca Jaslow; AnaMaria Lopez; Terrence Cescon; Wei Jiang; Ronald Myers; Qiang Wei; Bingshan Li; Massimo Cristofanilli; Hushan Yang
Journal:  Cancers (Basel)       Date:  2022-06-10       Impact factor: 6.575

3.  The Combination of the CDK4/6 Inhibitor, Palbociclib, With the Vitamin D3 Analog, Inecalcitol, Has Potent In Vitro and In Vivo Anticancer Effects in Hormone-Sensitive Breast Cancer, But Has a More Limited Effect in Triple-Negative Breast Cancer.

Authors:  Justine Vanhevel; Lieve Verlinden; Shauni Loopmans; Stefanie Doms; Iris Janssens; Sien Bevers; Steve Stegen; Hans Wildiers; Annemieke Verstuyf
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-17       Impact factor: 6.055

Review 4.  A review on the role of cyclin dependent kinases in cancers.

Authors:  Soudeh Ghafouri-Fard; Tayyebeh Khoshbakht; Bashdar Mahmud Hussen; Peixin Dong; Nikolaus Gassler; Mohammad Taheri; Aria Baniahmad; Nader Akbari Dilmaghani
Journal:  Cancer Cell Int       Date:  2022-10-20       Impact factor: 6.429

Review 5.  Targeting CDK4 and CDK6 in cancer.

Authors:  Shom Goel; Johann S Bergholz; Jean J Zhao
Journal:  Nat Rev Cancer       Date:  2022-03-18       Impact factor: 69.800

6.  CRLF2 overexpression results in reduced B-cell differentiation and upregulated E2F signaling in the Dp16 mouse model of Down syndrome.

Authors:  Jacob J Junco; Barry Zorman; Vincent U Gant; Jaime Muñoz; H Daniel Lacorazza; Pavel Sumazin; Karen R Rabin
Journal:  Exp Hematol       Date:  2022-03-17       Impact factor: 3.249

Review 7.  Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma.

Authors:  Rebecca A Sager; Sarah J Backe; Elham Ahanin; Garrett Smith; Imad Nsouli; Mark R Woodford; Gennady Bratslavsky; Dimitra Bourboulia; Mehdi Mollapour
Journal:  Nat Rev Urol       Date:  2022-03-09       Impact factor: 16.430

8.  Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells.

Authors:  Reeja S Maskey; Fang Wang; Elyssa Lehman; Yiqun Wang; Natasha Emmanuel; Wenyan Zhong; Guixian Jin; Robert T Abraham; Kim T Arndt; Jeremy S Myers; Anthony Mazurek
Journal:  Cell Cycle       Date:  2020-12-28       Impact factor: 4.534

9.  MicroRNA-186-3p attenuates tumorigenesis of cervical cancer by targeting MCM2.

Authors:  Xiurong Lu; Xiao Song; Xiaohui Hao; Xiaoyu Liu; Xianyu Zhang; Na Yuan; Huan Ma; Zhilin Zhang
Journal:  Oncol Lett       Date:  2021-05-19       Impact factor: 2.967

10.  Cell Cycle Regulatory Protein Expression in Multinucleated Giant Cells of Giant Cell Tumor of Bone: do They Proliferate?

Authors:  Mate E Maros; Peter Balla; Tamas Micsik; Zoltan Sapi; Miklos Szendroi; Holger Wenz; Christoph Groden; Ramses G Forsyth; Piero Picci; Tibor Krenacs
Journal:  Pathol Oncol Res       Date:  2021-05-03       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.